Literature DB >> 15165299

Aerosolized prostacyclins.

Mark Siobal1.   

Abstract

Two prostacyclins (prostaglandin E(1) and prostaglandin I(2)) are potent vasodilators. Aerosolized prostacyclins reduce pulmonary artery pressure, improve right heart function, and increase arterial oxygenation by improving ventilation/perfusion matching. This report describes aerosolized prostacyclins and compares them to inhaled nitric oxide. I review the types of inhalable prostacyclins and their indications, evidence of efficacy, delivery, and adverse effects.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15165299

Source DB:  PubMed          Journal:  Respir Care        ISSN： 0020-1324            Impact factor:   2.258


  4 in total

Review 1.  Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS).

Authors:  Arash Afshari; Anders Bastholm Bille; Mikkel Allingstrup
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

Review 2.  Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient.

Authors:  Michael D Davis; Steven M Donn; Robert M Ward
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

3.  Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration.

Authors:  Ralf Geiger; Axel Kleinsasser; Stephan Meier; Nikolaus Neu; Werner Pajk; Victoria Fischer; Benedict Treml; Joerg I Stein; Alexander Loeckinger
Journal:  Intensive Care Med       Date:  2007-09-27       Impact factor: 17.440

4.  Beyond the evidence: treating pulmonary hypertension in the intensive care unit.

Authors:  Seth R Bauer; Adriano R Tonelli
Journal:  Crit Care       Date:  2014-10-16       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.